United Capital Financial Advisors LLC Has $1.84 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

United Capital Financial Advisors LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 64.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,859 shares of the medical research company’s stock after purchasing an additional 9,779 shares during the period. United Capital Financial Advisors LLC’s holdings in Edwards Lifesciences were worth $1,840,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the 4th quarter valued at about $30,000. Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $54,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the subject of a number of recent research reports. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Truist Financial reduced their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $78.55.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $71.56 on Friday. The company has a market capitalization of $42.07 billion, a PE ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a 50 day simple moving average of $71.31 and a two-hundred day simple moving average of $70.85.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.